Submitted by Anonymous (not verified) on 8 November 2023 - 15:22
Human medicines European public assessment report (EPAR): Nuvaxovid, COVID-19 Vaccine (recombinant, adjuvanted), COVID-19 virus infection, Date of authorisation: 20/12/2021, Revision: 11, Status: Authorised
Source: